Jonathan Gardner is a Senior Reporter at BioPharma Dive. He specializes in medicine and healthcare, covering topics such as pharmaceuticals, biotech, and the FDA, with a keen focus on the impact of data and developments related to the Coronavirus. His work has been featured in notable publications including Healthcare Dive, WBUR, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
August 1, 2006 | Rheumatology News Author and Disclosure Information
August 1, 2006 | Rheumatology News Author and Disclosure Information
By: Ned Pagliarulo, Delilah Alvarado, Jonathan Gardner
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ramp-up in sales this year.
By: Gwendolyn Wu, Jonathan Gardner, Ben Fidler
Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended that Keytruda's coming loss of exclusivity can be managed.
In This Article AMGN LLY MRK VKTX
By: Ned Pagliarulo, Gwendolyn Wu, Jonathan Gardner
AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained what it got wrong forecasting GLP-1 drug demand.
By: Jonathan Gardner
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
By: Gwendolyn Wu, Jonathan Gardner
In This Article ABBV NVS LLY
By: Jonathan Gardner
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market opportunity analysts estimate to be worth about $500 million annually.
(833) 317-6278 
